首页 / 产品 / 蛋白 / 其他蛋白

Recombinant Human ABO protein

  • 中文名: ABO血型系统转移酶(ABO)重组蛋白
  • 别    名: ABO;Histo-blood group ABO system transferase
货号: PA1000-20DB
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90% by SDS-PAGE.
种属Human
靶点ABO
Uniprot NoP16442
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间54-354aa
氨基酸序列AVREPDHLQRVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP
预测分子量37 kDa 
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于ABO重组蛋白的3篇参考文献示例,按简化格式整理:

---

1. **"Molecular genetic basis of the histo-blood group ABO system"**

*Yamamoto, F., et al.*

该研究首次克隆了人类ABO血型系统的糖基转移酶基因,通过重组蛋白技术在大肠杆菌中表达,证实了A/B抗原合成酶的活性差异源于关键氨基酸替换。

2. **"Expression of recombinant ABO blood group enzymes in vitro for transfusion medicine"**

*Kruskall, M.S., et al.*

文章探讨了利用哺乳动物细胞系表达重组ABO酶,用于体外红细胞抗原改造,验证了重组酶在血型兼容性转化中的潜在应用价值。

3. **"Structural and functional analysis of ABO glycosyltransferases"**

*Hakomori, S.I., et al.*

通过X射线晶体学解析重组ABO酶的3D结构,揭示了底物特异性决定区域,并发现特定结构域突变可改变酶对糖供体/受体的亲和力。

---

注:以上文献信息为示例性概括,实际引用需以具体论文内容为准。建议通过PubMed或Web of Science以关键词"ABO recombinant enzyme"或"ABO glycosyltransferase expression"检索最新研究。

背景信息

**Background of ABO Recombinant Proteins**

The ABO blood group system, discovered over a century ago, is critical in transfusion medicine and organ transplantation. It classifies human blood into types A, B, AB, and O based on carbohydrate antigens (A and B) on red blood cells. These antigens are synthesized by glycosyltransferases encoded by the *ABO* gene. Type A individuals express A-transferase, which adds N-acetylgalactosamine to the H antigen (produced by the *FUT1* gene), while type B individuals express B-transferase, adding galactose. Type O lacks functional A/B-transferase activity, retaining the unmodified H antigen.

Recombinant ABO proteins are engineered versions of these glycosyltransferases or related antigens, produced via genetic engineering in host systems like bacteria, yeast, or mammalian cells. Their development stems from the need to study antigen-antibody interactions, improve blood typing diagnostics, and address challenges in transfusion compatibility. For instance, recombinant enzymes enable large-scale synthesis of blood group antigens for diagnostic kits, reducing reliance on human-derived reagents.

Additionally, ABO recombinant proteins are explored for therapeutic applications. In organ transplantation, modifying donor organs with enzymes to cleave ABO antigens could mitigate immune rejection. Similarly, recombinant enzymes like endo-β-galactosidase are investigated for converting type A/B red blood cells to "universal" type O, potentially easing blood supply shortages.

Advances in protein engineering, such as structure-guided mutagenesis, have optimized enzyme efficiency and specificity. However, challenges remain, including ensuring enzymatic stability *in vivo* and minimizing off-target effects. Ongoing research also focuses on understanding the structural basis of ABO antigen diversity and antibody recognition.

Overall, ABO recombinant proteins bridge molecular biology and clinical practice, offering tools to enhance blood compatibility, refine diagnostics, and pioneer novel therapies in personalized medicine.

客户数据及评论

折叠内容

大包装询价

×